Showing results (2091-2100 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|March 8, 2006
Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementiasJerrold Hill, Howard Fillit, Simu K Thomas, et al.Pharmacoeconomics|January 19, 2006
Modelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaP S Chue, Bart Heeg, Erik Buskens, et al.Pharmacoeconomics|January 19, 2006
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USANatalie C Edwards, Julie C Locklear, Marcia F T Rupnow, et al.Pharmacoeconomics|February 1, 2006
Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UKPhil McEwan, Simon Dixon, Keshwar Baboolal, et al.Pharmacoeconomics|December 1, 2007
Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspectiveBart Heeg, Joep Damen, Ben Van HoutPharmacoeconomics|February 20, 2008
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastasesKate McKeage, Greg L PloskerPharmacoeconomics|April 24, 2008
Perspectives on patient-reported outcomes : content validity and qualitative research in a changing clinical trial environmentNancy Kline Leidy, Margaret VernonPharmacoeconomics|February 8, 2014
How to estimate productivity costs in economic evaluationsMarieke Krol, Werner BrouwerPharmacoeconomics|May 21, 2008
Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in CanadaDeborah A Marshall, Patrick R Douglas, Michael F Drummond, et al.Pharmacoeconomics|January 4, 2025
Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case StudyKathleen Manipis, Paula Cronin, Deborah Street, et al.Pageof 336